Synta Pharmaceuticals (SNTA) Announces Initiation Of Three Multicenter, Randomized Phase II/III Trials Of Ganetespib In Acute Myeloid Leukemia (AML) And High Risk Myelodysplastic Syndrome (MDS)
1/10/2014 8:53:16 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS. These trials are conducted under the auspices of the UK National Cancer Institute (NCRI) Haematological Oncology Study Group with investigators in Denmark, France, New Zealand, and the United Kingdom and under the sponsorship of Cardiff University, UK. Ganetespib, Synta’s lead anti-cancer drug candidate, inhibits the heat shock protein 90 (Hsp90) chaperone protein and is being studied in over 25 clinical trials, including an ongoing Phase 3 trial in advanced non-small cell lung cancer.
Help employers find you! Check out all the jobs and post your resume.